EE366 Healthcare Costs Comparison of Dupilumab Vs. Omalizumab, Benralizumab and Mepolizumab in Patients with Moderate-to-Severe Asthma: A US Payer Perspective
Abstract
Authors
KK Sheth F Joulain RH Stanford S Luthra Z Wang A Kuznik WH Cheng